SI2555790T1 - Terapevtska uporaba proteina beta2-mikroglobulina - Google Patents
Terapevtska uporaba proteina beta2-mikroglobulinaInfo
- Publication number
- SI2555790T1 SI2555790T1 SI201130922A SI201130922A SI2555790T1 SI 2555790 T1 SI2555790 T1 SI 2555790T1 SI 201130922 A SI201130922 A SI 201130922A SI 201130922 A SI201130922 A SI 201130922A SI 2555790 T1 SI2555790 T1 SI 2555790T1
- Authority
- SI
- Slovenia
- Prior art keywords
- therapeutic use
- microglobulin protein
- microglobulin
- protein
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Rehabilitation Therapy (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10290188A EP2374470A1 (fr) | 2010-04-08 | 2010-04-08 | Utilisation thérapeutique de la protéine Beta2m |
| US34661710P | 2010-05-20 | 2010-05-20 | |
| EP11717774.1A EP2555790B1 (en) | 2010-04-08 | 2011-04-06 | THERAPEUTIC USE OF THE ß2-MICROGLOBULIN PROTEIN |
| PCT/IB2011/051476 WO2011125029A1 (en) | 2010-04-08 | 2011-04-06 | THERAPEUTIC USE OF THE ß2m PROTEIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2555790T1 true SI2555790T1 (sl) | 2016-09-30 |
Family
ID=42315462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201130922A SI2555790T1 (sl) | 2010-04-08 | 2011-04-06 | Terapevtska uporaba proteina beta2-mikroglobulina |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20130017212A1 (sl) |
| EP (2) | EP2374470A1 (sl) |
| JP (3) | JP5955833B2 (sl) |
| KR (1) | KR101889564B1 (sl) |
| CN (2) | CN108159398A (sl) |
| BR (1) | BR112012025537A2 (sl) |
| CA (1) | CA2793940C (sl) |
| CY (1) | CY1117968T1 (sl) |
| DK (1) | DK2555790T3 (sl) |
| ES (1) | ES2588710T3 (sl) |
| HR (1) | HRP20161022T1 (sl) |
| HU (1) | HUE030420T2 (sl) |
| LT (1) | LT2555790T (sl) |
| PL (1) | PL2555790T3 (sl) |
| PT (1) | PT2555790T (sl) |
| RS (1) | RS55121B1 (sl) |
| RU (1) | RU2582389C2 (sl) |
| SI (1) | SI2555790T1 (sl) |
| SM (1) | SMT201600301B (sl) |
| WO (1) | WO2011125029A1 (sl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2374470A1 (fr) * | 2010-04-08 | 2011-10-12 | Beta Innov | Utilisation thérapeutique de la protéine Beta2m |
| CN102716379A (zh) * | 2012-06-25 | 2012-10-10 | 毕建飞 | 一种治疗强直性脊柱炎的中药组合物 |
| CN116515000A (zh) * | 2023-06-30 | 2023-08-01 | 迦进生物医药(上海)有限公司 | Hfe融合蛋白及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| JPH05506447A (ja) * | 1990-05-10 | 1993-09-22 | ザ ダナーファーバー キャンサー インスチチュート | β↓２―ミクログロブリンを伴い抗原供給細胞表面上で外来ペプチッドのクラスＩＭＨＣ分子との会合を増進させる方法 |
| JPH07118163A (ja) * | 1993-10-21 | 1995-05-09 | Mitsui Toatsu Chem Inc | β２−ミクログロブリンを含有する組成物 |
| FR2735984B1 (fr) * | 1995-06-30 | 1997-09-19 | Inst Nat Sante Rech Med | Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic |
| US6100891A (en) | 1998-06-09 | 2000-08-08 | Teledirect International, Inc. | Call center agent interface and development tool |
| DE60030450T2 (de) * | 1999-09-08 | 2007-08-30 | Transgene S.A. | Von MUC-1 abgeleitete Peptide |
| WO2002024929A2 (en) * | 2000-09-22 | 2002-03-28 | Ramot At Tel Aviv University Ltd | A SOLUBLE BETA 2 MICROGLOBULIN (β2M)/HFE MONOCHAIN FOR BIOTECHNOLOGICAL AND THERAPEUTIC APPLICATIONS |
| GB0115071D0 (en) * | 2001-06-20 | 2001-08-15 | Avidex Ltd | Substances |
| KR20040040475A (ko) * | 2001-09-28 | 2004-05-12 | 가부시키가이샤 디나벡크 겐큐쇼 | 에피토프 결합 β２ｍ을 코드하는 포유동물 세포감염성 바이러스 벡터 및 그의 이용 |
| US7341721B2 (en) * | 2002-04-12 | 2008-03-11 | The Board Of Trustees Of The University Of Arkansas | β2-microglobulin (β2m) and anti-β2m binding agents as anti-cancer therapeutics |
| US20040127445A1 (en) | 2002-08-28 | 2004-07-01 | Chondrogene Limited | Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation |
| US20060286084A1 (en) | 2003-09-30 | 2006-12-21 | Yoshikazu Morita | Agent for promoting osteogenesis and/or inhibiting bone resorption |
| JP4740531B2 (ja) * | 2003-09-30 | 2011-08-03 | 雪印乳業株式会社 | 骨吸収抑制剤 |
| EP2374470A1 (fr) * | 2010-04-08 | 2011-10-12 | Beta Innov | Utilisation thérapeutique de la protéine Beta2m |
| CN112303586A (zh) | 2019-07-31 | 2021-02-02 | 华域视觉科技(上海)有限公司 | 车辆照明装置、车辆大灯及车辆 |
-
2010
- 2010-04-08 EP EP10290188A patent/EP2374470A1/fr not_active Withdrawn
-
2011
- 2011-04-06 PT PT117177741T patent/PT2555790T/pt unknown
- 2011-04-06 ES ES11717774.1T patent/ES2588710T3/es active Active
- 2011-04-06 WO PCT/IB2011/051476 patent/WO2011125029A1/en active Application Filing
- 2011-04-06 JP JP2013503207A patent/JP5955833B2/ja active Active
- 2011-04-06 LT LTEP11717774.1T patent/LT2555790T/lt unknown
- 2011-04-06 SI SI201130922A patent/SI2555790T1/sl unknown
- 2011-04-06 RU RU2012147460/15A patent/RU2582389C2/ru active
- 2011-04-06 CN CN201711451897.XA patent/CN108159398A/zh active Pending
- 2011-04-06 CA CA2793940A patent/CA2793940C/en active Active
- 2011-04-06 HU HUE11717774A patent/HUE030420T2/en unknown
- 2011-04-06 CN CN2011800209596A patent/CN102869368A/zh active Pending
- 2011-04-06 DK DK11717774.1T patent/DK2555790T3/en active
- 2011-04-06 RS RS20160725A patent/RS55121B1/sr unknown
- 2011-04-06 EP EP11717774.1A patent/EP2555790B1/en active Active
- 2011-04-06 PL PL11717774.1T patent/PL2555790T3/pl unknown
- 2011-04-06 BR BR112012025537A patent/BR112012025537A2/pt not_active Application Discontinuation
- 2011-04-06 US US13/636,438 patent/US20130017212A1/en not_active Abandoned
- 2011-04-06 KR KR1020127029186A patent/KR101889564B1/ko active IP Right Grant
-
2016
- 2016-02-05 JP JP2016020393A patent/JP2016145208A/ja active Pending
- 2016-08-16 HR HRP20161022TT patent/HRP20161022T1/hr unknown
- 2016-09-05 CY CY20161100870T patent/CY1117968T1/el unknown
- 2016-09-06 SM SM201600301T patent/SMT201600301B/it unknown
- 2016-10-20 US US15/298,757 patent/US11484571B2/en active Active
-
2017
- 2017-12-27 JP JP2017250624A patent/JP6703973B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2374470A1 (fr) | 2011-10-12 |
| PL2555790T3 (pl) | 2016-12-30 |
| WO2011125029A1 (en) | 2011-10-13 |
| CN108159398A (zh) | 2018-06-15 |
| PT2555790T (pt) | 2016-09-09 |
| BR112012025537A2 (pt) | 2016-06-21 |
| US11484571B2 (en) | 2022-11-01 |
| HRP20161022T1 (hr) | 2016-10-21 |
| JP2013523808A (ja) | 2013-06-17 |
| RS55121B1 (sr) | 2016-12-30 |
| RU2012147460A (ru) | 2014-05-20 |
| KR101889564B1 (ko) | 2018-08-17 |
| LT2555790T (lt) | 2016-09-12 |
| CY1117968T1 (el) | 2017-05-17 |
| JP2018076356A (ja) | 2018-05-17 |
| JP2016145208A (ja) | 2016-08-12 |
| EP2555790B1 (en) | 2016-06-08 |
| US20130017212A1 (en) | 2013-01-17 |
| KR20130086133A (ko) | 2013-07-31 |
| JP5955833B2 (ja) | 2016-07-20 |
| SMT201600301B (it) | 2016-11-10 |
| JP6703973B2 (ja) | 2020-06-03 |
| CA2793940C (en) | 2019-07-09 |
| EP2555790A1 (en) | 2013-02-13 |
| US20170035846A1 (en) | 2017-02-09 |
| CN102869368A (zh) | 2013-01-09 |
| DK2555790T3 (en) | 2016-09-12 |
| RU2582389C2 (ru) | 2016-04-27 |
| HUE030420T2 (en) | 2017-05-29 |
| ES2588710T3 (es) | 2016-11-04 |
| CA2793940A1 (en) | 2011-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181615T1 (hr) | Terapijsko sredstvo koje izaziva citotoksičnost | |
| EP2542086A4 (en) | COMPOUNDS AND ITS THERAPEUTIC USE | |
| EP2739144A4 (en) | COMPOUNDS AND ITS THERAPEUTIC USE | |
| ZA201301601B (en) | Treatment of diseases | |
| GB201004020D0 (en) | New therapeutic use | |
| EP2613786A4 (en) | TREATMENT OF DISEASES | |
| IL223667B (en) | 4a100s antibodies and medical uses thereof | |
| HK1201454A1 (en) | Therapeutic agents and uses thereof | |
| EP2605786A4 (en) | THERAPEUTIC PEPTIDES | |
| GB201011411D0 (en) | Therapeutic compounds and their use | |
| GB201005394D0 (en) | Therapy | |
| RS55121B1 (sr) | Terapeutska primena proteina ss2-mikroglobulina | |
| HK1182712A1 (en) | Therapeutic agents 976 976 | |
| GB201016864D0 (en) | Therapeutic methods | |
| GB201021708D0 (en) | Novel Therapeutic use | |
| GB201019938D0 (en) | Determination of therapeutic agents | |
| GB201014963D0 (en) | Therapeutic agents | |
| GB201012100D0 (en) | Therapeutic agents | |
| GB201012101D0 (en) | Therapeutic agents | |
| GB201012102D0 (en) | Therapeutic agents | |
| GB201010582D0 (en) | Therapeutic agents | |
| GB201010583D0 (en) | Therapeutic agents | |
| GB201010577D0 (en) | Therapeutic agents | |
| GB201009614D0 (en) | Therapeutic use of compounds | |
| GB0921430D0 (en) | Protein for therapeutic use |